B6E.HA - Swedish Orphan Biovitrum AB

Hanover - Hanover Delayed Price. Currency in EUR
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
17,696,000
18,790,000
15,529,000
15,261,000
14,248,000
Cost of revenue
4,484,000
4,776,000
3,484,000
3,225,000
3,335,000
Gross profit
13,212,000
14,014,000
12,045,000
12,036,000
10,913,000
Operating expenses
Research development
2,265,000
2,354,000
1,994,000
1,594,000
1,495,000
Selling general and administrative
7,550,000
7,847,000
6,294,000
5,981,000
4,935,000
Total operating expenses
9,735,000
10,169,000
8,258,000
7,573,000
6,414,000
Operating income or loss
3,477,000
3,845,000
3,787,000
4,463,000
4,499,000
Interest expense
458,000
458,000
419,000
454,000
241,000
Income before tax
2,978,000
3,321,000
3,295,000
4,217,000
4,247,000
Income tax expense
485,000
683,000
616,000
972,000
942,000
Income from continuing operations
2,493,000
2,638,000
2,679,000
3,245,000
3,305,000
Net income
2,493,000
2,638,000
2,679,000
3,245,000
3,304,000
Net income available to common shareholders
2,493,000
2,638,000
2,679,000
3,245,000
3,304,000
Basic EPS
-
8.92
9.08
11.01
11.29
Diluted EPS
-
8.84
9.03
10.90
11.22
Basic average shares
-
295,604
295,051
294,658
292,649
Diluted average shares
-
298,448
296,799
297,640
294,528
EBITDA
-
6,198,000
5,720,000
6,694,000
6,077,000